TY - JOUR
T1 - Liraglutide treatment is associated with progression of coronary artery fibrous plaque
T2 - a prospective 1-year follow-up study in asymptomatic patients with type 2 diabetes
AU - Heinsen, Laurits Juhl
AU - Pararajasingam, Gokulan
AU - Andersen, Thomas Rueskov
AU - Auscher, Søren
AU - Sheta, Hussam Mahmoud
AU - Precht, Helle
AU - Engdam, Kalle Brunebjerg
AU - Hangaard, Jørgen
AU - Lambrechtsen, Jess
AU - Knop, Filip Krag
AU - Egstrup, Kenneth
N1 - © 2023. The Author(s).
PY - 2023/4/28
Y1 - 2023/4/28
N2 - OBJECTIVE: The objective of this study was to assess the association between clinically indicated liraglutide treatment and coronary artery plaque progression during 1-year follow-up in asymptomatic diabetes.METHODS: Patients were divided into a group receiving liraglutide (Lira+) and a group not receiving liraglutide (Lira-). Coronary computed tomography angiography (CCTA) was performed to assess total atheroma volume (TAV) and subtypes of plaque volumes (dense calcium, fibrous, fibrous-fatty, and necrotic core plaque) and the plaque progression during one year follow-up.RESULTS: Fifty-five patients (27%) receiving liraglutide and 149 (73%) how did not were included. Changes in TAV during 1-year of follow-up were similar in the two groups (38 ± 180 (Lira+) vs. -1 ± 160 mm3 (Lira-), P = 0.13). A greater increase in fibrous plaque volume was seen in the Lira + vs. the Lira- group (34 ± 129 vs. -2 ± 101 mm3, P = 0.04). Changes over 1-year in the other plaque subtypes were similar in the two groups. Treatment duration of liraglutide was not associated with changes in TAV.CONCLUSION: In patients with T2D without known prior coronary artery disease, liraglutide treatment was associated with a significant increase in coronary artery fibrous plaque volume during 1-year follow-up.
AB - OBJECTIVE: The objective of this study was to assess the association between clinically indicated liraglutide treatment and coronary artery plaque progression during 1-year follow-up in asymptomatic diabetes.METHODS: Patients were divided into a group receiving liraglutide (Lira+) and a group not receiving liraglutide (Lira-). Coronary computed tomography angiography (CCTA) was performed to assess total atheroma volume (TAV) and subtypes of plaque volumes (dense calcium, fibrous, fibrous-fatty, and necrotic core plaque) and the plaque progression during one year follow-up.RESULTS: Fifty-five patients (27%) receiving liraglutide and 149 (73%) how did not were included. Changes in TAV during 1-year of follow-up were similar in the two groups (38 ± 180 (Lira+) vs. -1 ± 160 mm3 (Lira-), P = 0.13). A greater increase in fibrous plaque volume was seen in the Lira + vs. the Lira- group (34 ± 129 vs. -2 ± 101 mm3, P = 0.04). Changes over 1-year in the other plaque subtypes were similar in the two groups. Treatment duration of liraglutide was not associated with changes in TAV.CONCLUSION: In patients with T2D without known prior coronary artery disease, liraglutide treatment was associated with a significant increase in coronary artery fibrous plaque volume during 1-year follow-up.
KW - Humans
KW - Diabetes Mellitus, Type 2/diagnosis
KW - Plaque, Atherosclerotic/complications
KW - Follow-Up Studies
KW - Liraglutide/adverse effects
KW - Prospective Studies
KW - Coronary Artery Disease/diagnostic imaging
KW - Fibrosis
KW - Coronary Angiography/methods
KW - Computed Tomography Angiography/methods
UR - http://www.scopus.com/inward/record.url?scp=85156226558&partnerID=8YFLogxK
U2 - 10.1186/s12872-023-03228-5
DO - 10.1186/s12872-023-03228-5
M3 - Journal article
C2 - 37118678
SN - 1471-2261
VL - 23
SP - 214
JO - BMC Cardiovascular Disorders
JF - BMC Cardiovascular Disorders
IS - 1
M1 - 214
ER -